



# **INTEGRATION OF FARMIS-ONCOFARM® AND ONCOSAFETY RC® PHARMACY** SOFTWARES TO IMPROVE SAFETY IN THE ADMINISTRATION OF ANTINEOPLASTIC **DRUGS WITH INTELLIGENT INFUSION PUMPS**

ME Cárdaba García, S Fernández Peña, A Salvador Palacios, M Fernández Prieto, C González González, MT Sánchez Sánchez. Hospital Pharmacy, Hospital Clínico Universitario. Valladolid.

#### What was done?

The pharmacy softwares Farmis-Oncofarm® and Oncosafety-RC® were integrated to improve the prevention, detection and reduction of medication errors in the antineoplastic treatment administration phase at the OncoHaematology Day Hospital (OHDH). Subsequently, the results of this security strategy were evaluated.



## Why was it done?

Antineoplastic drugs, chemotherapy specifically, are a clear example of "high risk" medications. The drug administration phase, within the drug utilization circuit, is where the highest incidence of errors have been detected, ranging between 38%-81%, so the development and implementation of tools aimed at improving security at this stage is very important.

### How was it done?

A Drug Library was created in Farmis-Oncofarm® software (v.4.0.11.107). Parameters for the implantation of Oncosafety-RC® software were also defined. When the connectivity and integration between Farmis-Oncofarm® and Oncosafety RC® was validated, Oncosafety RC<sup>®</sup> was implemented in the OHDC.

To evaluate the results of the implementation of this strategy, a retrospective study from May-2022 to May-2023 was carried out. Collected data, obtained from Oncosafety RC® software were: number of mixtures (antineoplastic, supportive drugs and intravenous fluid therapy) and treatments administered, dose deviations, adverse events, incorrect infusion rates, errors avoided due to incorrect medication.

## What has been achieved?


## 12,294 treatments (44,898 mixtures) were administered in OHDC.



✓ Dose deviations were registered in the 0.01% of the mixtures, due to adverse events that required termination of the infusion.



 $\checkmark$  Only 3 adverse events happened in the study period.



 $\checkmark$  The infusion rate was incorrect in the 0.52% of the mixtures; this information is useful to improve administration and infusion-associated prevent



 This strategy prevented errors due to incorrect medication in 2,499 occasions.

## What next?

The integration between Farmis-Oncofarm® and Oncosafety RC® improved the security in the oncohaematological treatments administration phase, allowing the prevention, detection and reduction of medication errors.

This strategy could be implemented in hospitals that have assisted electronic prescription softwares, connection and information management softwares between different clinical management systems, and infusion pumps.

